Search clinical trials for: REGN3918

Total 29 results

Regeneron Pharmaceuticals

Completed

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

Healthy Volunteer

Belgium
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab

Paroxysmal Nocturnal Hemoglobinuria (PNH) | CD55-deficient Protein-losing Enteropathy (PLE) | CD59 Deficiency
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

CD55-Deficient Protein-Losing Enteropathy
Regeneron Pharmaceuticals

Terminated

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Korea, Republic of, Malaysia, Hungary, Taiwan, United Kingdom
Regeneron Pharmaceuticals

Active, not recruiting

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

CD55-deficient Protein-losing Enteropathy | CHAPLE

United States, Thailand, Turkey
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Hong Kong, Hungary, United Kingdom
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hong Kong, Hungary, Korea, Republic of, Malaysia, United Kingdom
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Healthy

United Kingdom
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Regeneron Pharmaceuticals

Completed

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)

Generalized Myasthenia Gravis

Korea, Republic of, Japan, Spain, United States, Germany, Italy, Canada, Georgia, India, Belgium, Poland, Taiwan, Australia, Denmark, France, Turkey, Serbia, United Kingdom, Czechia
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Long-term Safety, Tolerability, and Effectiveness of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS-EXT)

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Regeneron Pharmaceuticals

Completed

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Cat Allergy | Mild Asthma

France
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Allergy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Nesvacumab (REGN910/ SAR307746)

Solid Tumors

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

Corona Virus Infection

United States
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Allergic Rhinitis Due to Cat Allergy

United States, Belgium, Germany, Poland, Canada, France
Regeneron Pharmaceuticals

Completed

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Diabetic Macular Edema | Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

Paroxysmal Nocturnal Hemoglobinuria

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States, Belgium
Regeneron Pharmaceuticals

Recruiting

A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

Paroxysmal Nocturnal Hemoglobinuria

Mexico, Korea, Republic of, Turkey, Italy, United Kingdom, Thailand, Poland, Singapore, Spain, Taiwan, Canada, Japan, United States, Malaysia, Greece, Romania, Hungary
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
GlaxoSmithKline

Completed

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

Skin Infections, Bacterial

Netherlands, Costa Rica, Germany, Mexico, Canada, India, Poland, South Africa, France, Peru
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals
Bayer

Completed

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)

Diabetic Macular Edema

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Solid Tumors

United States, Canada

3

Subscribe